Home·Stocks·DNLI
Denali Therapeutics Inc. Common Stock

DNLI

XNAS

Denali Therapeutics Inc. Common Stock

Basic Materials · Biological Products, (No Diagnostic Substances)

$20.86
-0.09 (-0.43%)
15-min delayed

Drag to pan · Scroll to zoom · Hover for OHLC

Snapshot
Loading metrics…
About Denali Therapeutics Inc. Common Stock

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Employees
507
Country
US
IPO Date
2017-12-08
www.denalitherapeutics.com →
Recent News
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
SeekingAlpha · 3d ago
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35
Benzinga · 4d ago
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
SeekingAlpha · 4d ago
COMMUNITY · $DNLI0 theses
POST YOUR TAKE →
Analyst Ratings
Loading…
Financials
Loading SEC filings…
Insider Activity
Loading filings…
Related Stocks
Loading peers…
Ask AI about DNLIBuild basket with DNLIScreener

Data is 15-minute delayed, for informational purposes only. Not investment advice. Prices via Massive.com consolidated feed. Fundamentals via FinancialModelingPrep. News via Finnhub.

DNLI Denali Therapeutics Inc. Common Stock Stock — $20.86 -0.43% · AlgoThesis